Investigators are listed in full in Appendix 1 .
Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation
Article first published online: 30 SEP 2002
Volume 97, Issue 10, pages 1347–1354, October 2002
How to Cite
Berlin, I., Aubin, H.-J., Pedarriosse, A.-M., Rames, A., Lazabemide in Smoking Cessation Study Investigators, Lancrenon, S. and Gilbert Lagrue (2002), Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction, 97: 1347–1354. doi: 10.1046/j.1360-0443.2002.00258.x
- Issue published online: 30 SEP 2002
- Article first published online: 30 SEP 2002
- Submitted 12 November 2001; initial review completed 3 May 2002; final version accepted 17 June 2002
- Monoamine oxidase B inhibitor;
- randomized study;
- smoking cessation
Background Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is probably due to some components of tobacco smoke. When smokers quit, MAOB activity returns to normal. Reduced MAO activity may increase nicotine's addictive potential.
Aims To assess whether lazabemide, a reversible selective MAOB inhibitor, promotes smoking cessation.
Study design Double-blind, randomized, placebo-controlled, multicenter phase II study. Placebo, lazabemide 100 mg/day and 200 mg/day were administered for 8 weeks. This was a dose finding, proof-of-concept, exploratory study.
Setting General practices and anti-smoking clinics in France and Belgium.
Participants Smokers smoking ≥15 cigarettes per day and motivated to quit.
Main outcome measure Sustained abstinence during the last 4 weeks of the study.
Findings The study was discontinued prematurely by the sponsor before randomization of the planned 420 smokers because of liver toxicity observed in other indications. Data of 330 randomized subjects could be analysed. Sustained abstinence during the last 4 weeks of treatment was 9%, 11% and 17% in the intent-to-treat population [P for trend: 0.036 (one-sided)]; 11%, 14% and 21% in the intent-to-treat population of smokers without those excluded because of discontinuation of the study [n = 262, P for trend: 0.02 (one-sided)], and 19%, 27% and 35% in completers [P for trend: 0.03 (one-sided)], in the placebo, lazabemide 100 mg/day and lazabemide 200 mg/day groups, respectively. Point prevalence abstinence (intent-to-treat population) at the end of treatment (week 8) was 17%, 19% and 30% in the placebo, lazabemide 100 mg/day and lazabemide 200 mg/day groups, respectively (placebo vs. lazabemide 200 mg/day: P = 0.01, one-sided). No treatment emergent major adverse event occurred. More nausea and insomnia were reported with lazabemide than with placebo.
Conclusions MAOB inhibitors are promising treatments as an aid in smoking cessation. There may be an interest to develop MAOB inhibitors with an acceptable toxicity profile. Further studies may associate MAOB inhibitors with nicotine replacement therapies to increase therapeutic efficacy.